Figure S9 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Minae An; Arnav Mehta; Byung‐Hoon Min; You Jeong Heo; Samuel J. Wright; Milan Parikh; Lynn Bi; Hyuk Lee; Tae Jun Kim; Song-Yi Lee; Jeonghyeon Moon; Ryan J. Park; Matthew R. Strickland; Woong‐Yang Park; Won Ki Kang; Kyoung‐Mee Kim; Seung Tae Kim; Samuel J. Klempner; Jeeyun Lee

doi:10.1158/2159-8290.25728957.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Figure S9. (A) Cell type proportions from scSeq shown by individual patient split by individual high-level cell types across timepoints, color coded by fast vs slow progression status. (B) Cell type proportions from scSeq data by timepoint and fast vs slow progressor status including only GS and CIN patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

An et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db643587643677 https://doi.org/10.1158/2159-8290.25728957.v1

View Full Paper

Ask AI

Bookmark

Share

Figure S9 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Figure S9 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading